AR026087A1 - Aminoacidos biciclicos como agentes farmaceuticos. - Google Patents

Aminoacidos biciclicos como agentes farmaceuticos.

Info

Publication number
AR026087A1
AR026087A1 ARP000105497A ARP000105497A AR026087A1 AR 026087 A1 AR026087 A1 AR 026087A1 AR P000105497 A ARP000105497 A AR P000105497A AR P000105497 A ARP000105497 A AR P000105497A AR 026087 A1 AR026087 A1 AR 026087A1
Authority
AR
Argentina
Prior art keywords
aminomethyl
acetic acid
compounds
1alpha
octahydro
Prior art date
Application number
ARP000105497A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR026087A1 publication Critical patent/AR026087A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/20All rings being cycloaliphatic the ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/22All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/24All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/26All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)

Abstract

Se refiere a compuestos novedosos, sus sales aceptables farmacéuticamente y sus prodrogas, de formula 1, 2, 3 y 4 donde n es un entero desde 1 hasta 4,donde hay estereocentros, que pueden ser independientemente R o S. Comprende los siguientes compuesto: ácido(1alfa, 6alfa, 8beta)(2-aminometil-octahidro-inden-2-il)acético, ácido (2-aminometil-octahidro-inden-2-il) acético, ácido (2-aminometil-octahidro-pentalen-2-il) acético, ácido(3-aminometil-biciclo[3.2.0]hept-3-il) acético, También son preferidos los compuestos: ácido (1alfa, 5beta)(3-aminometil-biciclo[3.1.0]hex-3-il) acético, ácido (1alfa, 5beta)(2-aminometil-biciclo[3.2.0]hex-3-il) acético, ácido (1alfa, 5beta)(2-aminometil-octahidro-pentalen-2-il) acético, ácido (1alfa, 7beta)(2-aminometil-decahidro-azulen-2-il)acético. Se suministran ejemplos de las síntesis químicas de estos compuestos. También se describe una composicion farmacéutica que comprende dichos compuestosjunto con portadores solidos o líquidos aceptables, además decolorantes, saborizantes, estabilizadores, dispersantes, espesantes, solubilizantes y similares.Se presentan en forma de polvos, cápsulas, tabletas, píldoras, supositorios, gránulos, soluciones, suspensiones y emulsiones, para uso oral, inyeccion, etc.en dosis unitaria, siendo las dosis diarias de 0,01 mg/kg hasta 100 mg/kg. Se incluyen los usos de los compuestos para fabricar composiciones para tratamientode la epilepsia, ataques de desmayo, hipoquinesia, tratornos neuropatologicos y síndromepremestrual, administrando una cantidad terapéuticamente efectiva dedichos compuestos. Se compara en dichos compuestos la afinidad de union al radioligando mediante el uso de [3H]gabapentina con la unidad alfa2delta derivadadel tejido de cerebro porcino, que indican un comportamiento farmacologico comparable con la gabapentina. Se describen ensayos de hiperalgesia inducida porcarragenina, ataques tonicos inducidos por semicarbazida, uso de caja de luz/oscuridad para ratones, laberinto X para ratas, prueba de amenaza a titíes, pruebade conflicto de la rata, eficacia anticonvulsiva en ratones.
ARP000105497A 1999-10-20 2000-10-19 Aminoacidos biciclicos como agentes farmaceuticos. AR026087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
AR026087A1 true AR026087A1 (es) 2002-12-26

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000105497A AR026087A1 (es) 1999-10-20 2000-10-19 Aminoacidos biciclicos como agentes farmaceuticos.
ARP040102937A AR045456A2 (es) 1999-10-20 2004-08-17 Compuestos aminoacidos biciclicos, composicion farmaceutica y usos para fabricarla

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP040102937A AR045456A2 (es) 1999-10-20 2004-08-17 Compuestos aminoacidos biciclicos, composicion farmaceutica y usos para fabricarla

Country Status (50)

Country Link
US (2) US6689906B1 (es)
EP (2) EP1506955B1 (es)
JP (2) JP3632191B2 (es)
KR (2) KR100566462B1 (es)
CN (1) CN1165518C (es)
AP (2) AP2002002517A0 (es)
AR (2) AR026087A1 (es)
AT (2) ATE358116T1 (es)
AU (2) AU778871B2 (es)
BG (2) BG108860A (es)
BR (1) BR0014972B1 (es)
CA (1) CA2386297C (es)
CO (1) CO5280060A1 (es)
CR (1) CR6620A (es)
CU (1) CU23112A3 (es)
CZ (1) CZ295960B6 (es)
DE (2) DE60019628T2 (es)
DO (1) DOP2000000083A (es)
DZ (1) DZ3197A1 (es)
EA (1) EA005206B1 (es)
EC (1) ECSP045393A (es)
EE (1) EE200200211A (es)
ES (2) ES2282785T3 (es)
GE (1) GEP20043297B (es)
GT (2) GT200000183AA (es)
HK (1) HK1049826B (es)
HN (1) HN2000000224A (es)
HR (2) HRP20020428B1 (es)
HU (1) HUP0203325A3 (es)
IL (3) IL149143A0 (es)
IS (2) IS6348A (es)
MA (1) MA26842A1 (es)
MX (1) MXPA02003229A (es)
MY (1) MY127678A (es)
NO (2) NO20021780L (es)
NZ (1) NZ517961A (es)
OA (1) OA12070A (es)
PA (1) PA8505201A1 (es)
PE (1) PE20010740A1 (es)
PL (1) PL354607A1 (es)
PT (1) PT1226110E (es)
SI (1) SI1226110T1 (es)
SK (1) SK5232002A3 (es)
SV (1) SV2001000188A (es)
TR (2) TR200201094T2 (es)
TW (2) TW200505824A (es)
UA (1) UA72931C2 (es)
WO (1) WO2001028978A1 (es)
YU (2) YU73004A (es)
ZA (1) ZA200202543B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
WO2002000209A2 (en) * 2000-06-26 2002-01-03 Warner-Lambert Company Gabapentin analogues for sleep disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
OA12504A (en) 2001-04-19 2006-05-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids.
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04004105A (es) * 2002-01-31 2004-11-29 Warner Lambert Co Metodo de tratamiento de tinnitus.
JP2005523281A (ja) * 2002-02-22 2005-08-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アルファ−2−デルタリガンドとシクロオキシゲナーゼ−2の選択的阻害剤との組合せ
AU2003239752A1 (en) * 2002-06-27 2004-01-19 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
EP1545491A1 (en) * 2002-08-15 2005-06-29 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
RU2353358C2 (ru) 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
ES2433890T3 (es) 2007-09-28 2013-12-12 Daiichi Sankyo Company, Limited Derivado de aminoácido bicíclico
KR101674700B1 (ko) 2009-03-26 2016-11-09 다이이찌 산쿄 가부시키가이샤 2고리성 γ-아미노산 유도체의 제조 방법
WO2012169475A1 (ja) 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
EP2719676B1 (en) 2011-06-08 2017-12-13 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via iminium salt
KR101944575B1 (ko) 2011-12-15 2019-04-17 다이이찌 산쿄 가부시키가이샤 부제 촉매를 사용하는 2고리형 화합물의 광학 분할 방법
CN104245951B (zh) 2012-04-10 2018-08-24 第一三共株式会社 使用酶对二环化合物光学拆分的方法
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ-胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PL199794B1 (pl) 1997-10-27 2008-10-31 Warner Lambert Co Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów

Also Published As

Publication number Publication date
IL149143A0 (en) 2002-11-10
AR045456A2 (es) 2005-10-26
DZ3197A1 (fr) 2001-04-26
HRP20020428B1 (en) 2006-02-28
SV2001000188A (es) 2001-09-07
GT200000183AA (es) 2005-06-17
HUP0203325A3 (en) 2003-12-29
CN1165518C (zh) 2004-09-08
DE60034157D1 (de) 2007-05-10
NO20043663L (no) 2002-04-16
ZA200202543B (en) 2003-09-23
MXPA02003229A (es) 2002-09-30
CA2386297A1 (en) 2001-04-26
EP1506955A1 (en) 2005-02-16
OA12070A (en) 2003-11-10
EP1226110B1 (en) 2005-04-20
EP1226110A1 (en) 2002-07-31
ECSP045393A (es) 2004-10-23
AP2004003186A0 (en) 2004-12-31
TW200505824A (en) 2005-02-16
AU1092001A (en) 2001-04-30
HRP20020428A2 (en) 2005-02-28
EE200200211A (et) 2003-06-16
UA72931C2 (uk) 2005-05-16
IS7497A (is) 2004-10-08
US20040152779A1 (en) 2004-08-05
JP3744928B2 (ja) 2006-02-15
DOP2000000083A (es) 2002-03-30
BR0014972B1 (pt) 2011-09-06
MY127678A (en) 2006-12-29
ATE358116T1 (de) 2007-04-15
JP3632191B2 (ja) 2005-03-23
PA8505201A1 (es) 2002-08-29
YU29302A (sh) 2005-06-10
KR100593349B1 (ko) 2006-06-26
IS6348A (is) 2002-04-17
EA200200293A1 (ru) 2002-10-31
AP2002002517A0 (en) 2002-06-30
SI1226110T1 (en) 2005-08-31
US6835751B2 (en) 2004-12-28
HUP0203325A2 (hu) 2003-02-28
AU2005201268A1 (en) 2005-04-21
TR200201094T2 (tr) 2002-09-23
HN2000000224A (es) 2001-04-11
CA2386297C (en) 2010-02-09
HK1049826A1 (en) 2003-05-30
DE60019628D1 (de) 2005-05-25
JP2003512348A (ja) 2003-04-02
DE60019628T2 (de) 2006-01-19
NO20021780D0 (no) 2002-04-16
PE20010740A1 (es) 2001-07-27
PL354607A1 (en) 2004-01-26
NO20021780L (no) 2002-04-16
KR100566462B1 (ko) 2006-03-31
US6689906B1 (en) 2004-02-10
BG106719A (bg) 2003-02-28
IL164060A0 (en) 2005-12-18
DE60034157T2 (de) 2007-12-13
CO5280060A1 (es) 2003-05-30
EP1506955B1 (en) 2007-03-28
CZ20021310A3 (cs) 2003-05-14
HRP20040709A2 (en) 2004-12-31
YU73004A (sh) 2005-11-28
CN1382118A (zh) 2002-11-27
TWI225855B (en) 2005-01-01
PT1226110E (pt) 2005-07-29
CR6620A (es) 2004-02-02
BG108860A (en) 2006-03-31
AU778871B2 (en) 2004-12-23
KR20020040900A (ko) 2002-05-30
BR0014972A (pt) 2002-07-16
JP2005036009A (ja) 2005-02-10
MA26842A1 (fr) 2004-12-20
EA005206B1 (ru) 2004-12-30
HK1049826B (zh) 2005-02-25
ATE293590T1 (de) 2005-05-15
TR200500221T2 (tr) 2005-03-21
IL149143A (en) 2007-02-11
NZ517961A (en) 2002-12-20
ES2282785T3 (es) 2007-10-16
CZ295960B6 (cs) 2005-12-14
WO2001028978A1 (en) 2001-04-26
SK5232002A3 (en) 2003-07-01
CU23112A3 (es) 2006-02-27
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
ES2237464T3 (es) 2005-08-01
KR20060013701A (ko) 2006-02-13

Similar Documents

Publication Publication Date Title
AR026087A1 (es) Aminoacidos biciclicos como agentes farmaceuticos.
ES2260850T3 (es) Aminoaciods ciclicos y sus derivados utiles como agentes farmaceuticos.
UY25148A1 (es) Método para producir una composición farmacéutica que comprende un análogo de ácido gama aminobutírico (gaba) y una droga antiinflamatoria no esteroide (nsaid)
NO142172B (no) Analogifremgangsmaate for fremstilling av som antikonvulsiva virksomme alfa-fenyl-benzyliden-aminosyrederivater
AR035861A1 (es) Compuestos aminoacidos biciclicos o triciclicos condensados, procedimiento de preparacion, composiciones farmaceuticas y su uso en la preparacion de medicamentos
GB1575850A (en) Carboxyalkylacylamino acids
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
SK283295B6 (sk) Substituovaná cyklická aminokyselina, jej použitie a farmaceutický prostriedok na jej báze
ATE208397T1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
JPH07508288A (ja) 抗発作治療用のgaba及びl−グルタミン酸類縁体
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
DE69305492T2 (de) Im intracerebralen bereich verweisende verbindungen und deren anwendung
ATE265998T1 (de) Propancarbonsäure-amidoxim derivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese entahlten
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
PE20021016A1 (es) Conjugados de pregabalina-lactosa
EA199800155A1 (ru) Новое соединение
Martin et al. Pregabalin
YU41602A (sh) Postupak za stereoselektivnu sintezu cikličnih aminokiselina
ITMI942362A1 (it) Procedimento per la preparazione di una combinazione chimica farmacologicamente attiva
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2'cloro-6'-fluoroanilino)fenilacético
BR0011039A (pt) Análogos de gaba substituìdos com 3-heteroarilalquila
ECSP003726A (es) Aminoacidos biciclicos como agentes farmaceuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure